Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate pneumonia.
Description: All adverse event recording
Measure: To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate. Time: 2 weeksDescription: The percentage of patients improving the clinical and respiratory parameters compared with controls.
Measure: To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters. Time: 2 weeksDescription: The percentage of ICU admission in baricitinib group as compared with controls.
Measure: ICU admission rate Time: 2 weeksDescription: The percentage of discharged in baricitinib group as compared with controls.
Measure: Discharge rate. Time: 2 weeks